1. 1 ICON Quarter 4, 2008 Results ended December 31, 2008 Dr. John Climax, Chairman Mr. Peter Gray, CEO Mr. Ciaran Murray, CFO

2. 2 Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward Looking Statement

3. 3 Quarterly Net Revenue Growth

4. 4 Annual Net Revenue Growth

5. 5 Quarterly Operating Income

6. 6 Annual Operating Income (After charging non-cash stock compensation expense (SFAS123R))

7. 7 Operating Margins (After charging non-cash stock compensation expense (SFAS123R))

8. 8 Clinical Core Operating Margin (After charging non-cash stock compensation expense (SFAS123R))

9. 9 Central Laboratory Operating Margin (After charging non-cash stock compensation expense (SFAS123R))

10. 10 Quarterly Earnings per Share and Net Income

11. 11 Dec 31, 2008Dec 31, 2007 Net Cash/(Debt) (4.3)23.8 Net Accounts Receivable230.3178.0 DSOs69 Days66 Days Balance Sheet $ million

12. 12  Outlook

13. 13 Business Wins

14. 14 Total Backlog

15. 15 Backlog forecast to be earned in the next 12 months (US$ & % of total forecasts)

16. 16 Questions & Answers Dr John Climax, Chairman Mr Peter Gray, CEO Mr Ciaran Murray, CFO

17. 17 FY 08 net revenues ↑ 37% FY 08 income from operations ↑ 44% FY 08 operating margin of 11.5% FY 08 EPS ↑ 38% $1.3 billion of net new business wins Book-to-bill ratio 1.5 Summary FY, 2008